Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.63 |
| ▸ | THRB | P10828 | 7/20 | 0.63 |
| ▸ | BLM | P54132 | 6/20 | 0.63 |
| ▸ | TOP2A | P11388 | 5/20 | 0.63 |
| ▸ | RECQL | P46063 | 5/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | BRCA1 | P38398 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 4/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.63 |
| ▸ | FYN | P06241 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1103790 | 0.91 | MEN1 (0.67) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL14706187 | 0.90 | MEN1 (0.73) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL14703485 | 0.90 | MEN1 (0.73) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL18751205 | 0.90 | MEN1 (0.73) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL17897684 | 0.89 | MEN1 (0.76) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL330074 | 0.89 | MEN1 (0.76) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL17897710 | 0.89 | MEN1 (0.76) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL15304012 | 0.89 | MEN1 (0.76) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL18751650 | 0.87 | CHN2 (0.60) | MEN1KMT2ATHRBBLMTOP2A | |
| SCHEMBL10452484 | 0.86 | MEN1 (0.77) | MEN1KMT2ATHRBBLMTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300070-B2 | Metabolically-activated drug conjugates to overcome resistance in cancer therapy | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170105998-A1 | METABOLICALLY-ACTIVATED DRUG CONJUGATES TO OVERCOME RESISTANCE IN CANCER THERAPY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-04-20 | — | — | US | disclosed |
| US-20170105998-A1 | METABOLICALLY-ACTIVATED DRUG CONJUGATES TO OVERCOME RESISTANCE IN CANCER THERAPY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300070-B2 | Metabolically-activated drug conjugates to overcome resistance in cancer therapy | GOT2, GOT1, PCK2 | MEN1 2380/4885KMT2A 644/4885THRB 1025/4885 |
| US-20170105998-A1 | METABOLICALLY-ACTIVATED DRUG CONJUGATES TO OVERCOME RESISTANCE IN CANCER THERAPY | GOT2, GOT1, PCK2 | MEN1 2380/4885KMT2A 644/4885THRB 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.